Aridis Pharmaceuticals, Inc. – NASDAQ:ARDS
Aridis Pharmaceuticals stock price today
Aridis Pharmaceuticals stock price monthly change
Aridis Pharmaceuticals stock price quarterly change
Aridis Pharmaceuticals stock price yearly change
Aridis Pharmaceuticals key metrics
Market Cap | 4.45K |
Enterprise value | 16.15M |
P/E | -0.13 |
EV/Sales | 18.74 |
EV/EBITDA | -0.47 |
Price/Sales | 4.59 |
Price/Book | -0.11 |
PEG ratio | N/A |
EPS | -0.14 |
Revenue | N/A |
EBITDA | -633K |
Income | -635K |
Revenue Q/Q | N/A |
Revenue Y/Y | 2227.61% |
Profit margin | -3968.79% |
Oper. margin | -3775.17% |
Gross margin | 66.13% |
EBIT margin | -3775.17% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAridis Pharmaceuticals stock price history
Aridis Pharmaceuticals stock forecast
Aridis Pharmaceuticals financial statements
| Dec 2022 | 0 | -5.35M | |
|---|---|---|---|
| Mar 2023 | 0 | -7.34M | |
| Jun 2023 | 19.64M | 12.14M | 61.81% |
| Sep 2023 | 417K | -83K | -19.9% |
| 2025 | 75.92M | 27.60M | 36.36% |
|---|
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 0% |
|---|
| 2018 | 3.89% |
|---|---|
| 2019 | |
| 2020 | |
| 2021 | 14.41% |
| 2022 |
| Dec 2022 | 14695000 | 38.92M | 264.9% |
|---|---|---|---|
| Mar 2023 | 9434000 | 37.31M | 395.55% |
| Jun 2023 | 6482000 | 21.39M | 330.08% |
| Sep 2023 | 6534000 | 30.13M | 461.25% |
| Dec 2022 | -8.55M | -49K | 11.03M |
|---|---|---|---|
| Mar 2023 | -4.00M | 0 | 263K |
| Jun 2023 | -4.34M | 14K | 3.02M |
| Sep 2023 | -983K | 0 | 999K |
Aridis Pharmaceuticals alternative data
| Aug 2023 | 37 |
|---|---|
| Sep 2023 | 37 |
| Oct 2023 | 37 |
| Nov 2023 | 37 |
| Dec 2023 | 37 |
| Jan 2024 | 37 |
| Feb 2024 | 37 |
| Mar 2024 | 37 |
| Apr 2024 | 37 |
| May 2024 | 37 |
| Jun 2024 | 37 |
| Jul 2024 | 37 |
Aridis Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2021 | 12175 | 0 |
| Sep 2021 | 5100 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | PATZER ERIC director, officer: Executive Ch.. | Common Stock | 12,000 | N/A | N/A | ||
Option | PATZER ERIC director, officer: Executive Ch.. | Restricted Stock Units | 12,000 | N/A | N/A | ||
Option | HAMILTON JOHN F director | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | HAMILTON JOHN F director | Common Stock | 5,000 | N/A | N/A | ||
Option | TRUONG VU director, officer.. | Common Stock | 15,000 | N/A | N/A | ||
Option | TRUONG VU director, officer.. | Restricted Stock Units | 15,000 | N/A | N/A | ||
Option | WINDHAM-BANNISTER SUSAN RICHARDS director | Restricted Stock Units | 5,000 | N/A | N/A | ||
Option | WINDHAM-BANNISTER SUSAN RICHARDS director | Common Stock | 5,000 | N/A | N/A | ||
Option | JAFRI HASAN officer: Chief Medical Officer | Common Stock | 10,000 | N/A | N/A | ||
Option | JAFRI HASAN officer: Chief Medical Officer | Restricted Stock Units | 10,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 17 Mar 2020 Issue date: 16 Jun 2022 |
Application Method For Preparation of Quick Dissolving Thin Films Containing Bioactive Material With Enhanced Thermal Stability Filling date: 6 Jun 2017 Issue date: 21 Oct 2021 |
Application Filling date: 1 Oct 2018 Issue date: 16 Sep 2021 |
Grant Utility: Targets of Acinetobacter baumannii Filling date: 25 Sep 2019 Issue date: 16 Jun 2020 |
Grant Utility: Targets of Acinetobacter baumannii Filling date: 7 Sep 2018 Issue date: 31 Mar 2020 |
Grant Utility: Targets of Acinetobacter baumannii Filling date: 13 Feb 2018 Issue date: 31 Mar 2020 |
Application Filling date: 25 Sep 2019 Issue date: 16 Jan 2020 |
Grant Utility: Targets of acinetobacter baumannii Filling date: 15 Feb 2018 Issue date: 5 Nov 2019 |
Grant Utility: Targets of acinetobacter baumannii Filling date: 15 Feb 2018 Issue date: 24 Sep 2019 |
Grant Utility: Targets of Acinetobacter Baumannii Filling date: 14 Feb 2018 Issue date: 3 Sep 2019 |
| Insider | Compensation |
|---|---|
| Dr. Vu L. Truong (1964) Founder, Chief Executive Officer & Director | $566,120 |
-
What's the price of Aridis Pharmaceuticals stock today?
One share of Aridis Pharmaceuticals stock can currently be purchased for approximately $0.
-
When is Aridis Pharmaceuticals's next earnings date?
Unfortunately, Aridis Pharmaceuticals's (ARDS) next earnings date is currently unknown.
-
Does Aridis Pharmaceuticals pay dividends?
No, Aridis Pharmaceuticals does not pay dividends.
-
How much money does Aridis Pharmaceuticals make?
Aridis Pharmaceuticals has a market capitalization of 4.45K.
-
What is Aridis Pharmaceuticals's stock symbol?
Aridis Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "ARDS".
-
What is Aridis Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Aridis Pharmaceuticals?
Shares of Aridis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Aridis Pharmaceuticals's key executives?
Aridis Pharmaceuticals's management team includes the following people:
- Dr. Vu L. Truong Founder, Chief Executive Officer & Director(age: 61, pay: $566,120)
-
Is Aridis Pharmaceuticals founder-led company?
Yes, Aridis Pharmaceuticals is a company led by its founder Dr. Vu L. Truong.
-
How many employees does Aridis Pharmaceuticals have?
As Jul 2024, Aridis Pharmaceuticals employs 37 workers.
-
When Aridis Pharmaceuticals went public?
Aridis Pharmaceuticals, Inc. is publicly traded company for more then 7 years since IPO on 14 Aug 2018.
-
What is Aridis Pharmaceuticals's official website?
The official website for Aridis Pharmaceuticals is aridispharma.com.
-
Where are Aridis Pharmaceuticals's headquarters?
Aridis Pharmaceuticals is headquartered at 983 University Avenue, Los Gatos, CA.
-
How can i contact Aridis Pharmaceuticals?
Aridis Pharmaceuticals's mailing address is 983 University Avenue, Los Gatos, CA and company can be reached via phone at +40 83851742.
Aridis Pharmaceuticals company profile:
Aridis Pharmaceuticals, Inc.
aridispharma.comNASDAQ
37
Biotechnology
Healthcare
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-320 is a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR-105, a fully human IgG1 mAb, which is in Phase II trials to target gram-negative bacteria P. aeruginosa; AR-101, a human IgM mAb, which is in Phase IIa clinical trials for the treatment of hospital-acquired pneumonia (HAP)and ventilator-associated pneumonia (VAP) caused by P. aeruginosa serotype O11; AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-501, an anti-infective therapy, which is in Phase I/IIa clinical trial to manage chronic lung infections in cystic fibrosis patients. In addition, it is developing AR-712 and AR-701, a cocktail of two fully human immunoglobulin 1, or IgG1, mAbs, which is in Phase I/II clinical for the treatment of mild to moderate non-hospitalized COVID-19 patients. Aridis Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Los Gatos, California.
Los Gatos, CA 95032
CIK: 0001614067
ISIN: US0403341045
CUSIP: 040334104
